Scalable Platform ScaleReady collaboration with Fresenius Kabi and Bio-Techne positions Wilson Wolf as a gateway to scalable cell therapy manufacturing; target biotechs and CMOs building commercial T cell programs and offer end to end support from process development to scale up.

Automation Demand Recent Multiply Labs partnership signals growing demand for automation in G-Rex bioreactors; pursue opportunities to provide automation ready hardware, integration software, manufacturing data capture, and GMP compliant control solutions.

Immuno-Oncology Targets Active and past collaborations with IO players indicate strong traction in T cell therapy manufacturing; focus outreach to CAR-T and TCR developers seeking reliable, repeatable scale up capabilities and tailored workflows.

Growth Signals Strategic investments and potential future acquisitions highlight growth potential and partner interest; frame value proposition around scalable, efficient processes that align with clinical and commercial development timelines.

Regional Access Minnesota base with global partnerships enables regional service and support for US labs and startups; leverage ScaleReady ecosystem to connect clients with a network of collaborators and accelerate implementation.